CA-INSEEGO
19.7.2022 13:03:57 CEST | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG), a leader in 5G edge cloud solutions, today announced the release of Inseego 5G SD EDGE™ for enterprises, a 5G cloud networking solution that delivers networking and security through a 5G network fabric, thereby eliminating the need for complex, expensive, on-premise custom legacy hardware solutions. The Inseego 5G SD EDGE cloud enables the industry's first zero trust network access (ZTNA) solution with distributed security and granular IT control designed exclusively for 5G networks. This new solution follows a novel approach to create a thin edge that is cloud controlled and makes digital transformation simple, fast, and affordable for enterprises of all sizes.
The pandemic revolutionized the workplace, and as a result, enterprises worldwide are seeking cost-effective solutions to securely connect their distributed sites and workforce. There has been a lack of innovation regarding this trend, and the current market solutions are not equipped to scale the growing remote workforce. Inseego’s 5G SD EDGE was designed specifically to address this need as it provides a cost-effective solution that can scale quickly into thousands of distributed locations fully controlled by corporate IT security protocols.
Inseego's 5G SD EDGE solution enables enterprises to deliver better and more secure experiences to their employees and distributed sites, irrespective of their locations.
- 5G WWAN: Inseego's 5G SD EDGE leverages Inseego’s entire industry-leading 5G FWA portfolio and delivers gigabit speeds at the edge over a secure 5G Wireless WAN (WWAN) that can be deployed in minutes anywhere around the world.
- Extend corporate Wi-Fi across a distributed enterprise: The solution extends the plug-and-play corporate LAN experience to remote worker homes and distributed company sites, resulting in reliable and secure 5G connectivity at the edge, wherever business happens.
- Automate and orchestrate processes for simplified, responsive and efficient IT: Corporate IT departments can easily manage and configure network traffic prioritization, device management, and security from a single pane of glass with unified policies and compliance.
- Secure the distributed edge: The Inseego 5G SD EDGE solution extends corporate IT with ZTNA components for the first time into the 5G network fabric, providing inherent security, encryption, tunneling, authentication, threat prevention, and much more.
- Cost savings: Most traditional IT networks comprise piecemeal components from multiple legacy vendors, such as SD-WAN, connectivity, security, and networking, resulting in more costly and labor-intensive operation compared with an integrated wireless solution. Inseego 5G SD EDGE integrates 5G, wired connections, security, and networking functions, such as segmentation, traffic prioritization, load balancing, and other features, into a single solution, resulting in lower costs.
“Today, the demand for real-time experiences and tightened security is greater than ever, since business is happening everywhere, not just in the corporate office. When it comes to meeting that demand, a 5G WWAN corporate IT network is far more robust than any wired network for consistent and reliable IT and OT experiences at the edge,” said Ritesh Mukherjee, Senior Vice President & General Manager, Enterprise Networks at Inseego. “The release of the Inseego 5G SD EDGE cloud networking solution is a major innovation for the IT solutions world, which currently comprises of disparate and modular components that are pieced together by pricey vendors and designed to support a wired world, with wireless considered an add-on for backhaul. Inseego’s innovation brings SD-WAN, ZTNA, bonding of multiple wireless and wired connections, and remote management capabilities to 5G WWAN networks in a simple package for a fraction of the cost of traditional, modular solutions.”
“The number of distributed sites and remote workforces is unprecedented and has affected not only the way we work, but how IT organizations are evolving the corporate IT network. They are seeking to provide the corporate Wi-Fi experience to wherever business happens, which means excellent, reliable connectivity delivering gigabit performance and security beyond encryption that is just as robust outside as it is on-premise,” said Ray Mota, CEO and principal analyst of ACG Research. “By integrating ZTNA with a robust 5G cloud WAN, Inseego’s 5G SD EDGE solution is transforming enterprise cloud networking for IT organizations. By eliminating the need for reliance on traditional broadband connections, clunky piecemeal solutions, and security that enables risk-appropriate access to resources from any device at any time and from any location, Inseego has made a 5G-enabled enterprise a reality.”
The Inseego 5G SD EDGE solution is currently in trials with Fortune 500 enterprise customers in target markets. It is subscription-based and available globally through channel partners and directly to enterprises. For more information, visit: https://inseego.com/solutions/remote-employees/ .
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in intelligent device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency, and strong security to deliver highly reliable internet access. Inseego's mobile broadband, fixed wireless access (FWA) solutions, and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6, and others) into a wide range of innovative products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Inseego's products and SaaS solutions that provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide are designed and developed in the USA. www.inseego.com
#Putting5GtoWork
©2022. Inseego Corp. All rights reserved. The Inseego name and logo and Inseego 5G SD EDGE are trademarks of Inseego Corp. Other company, product, or service names mentioned herein are the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005500/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom